Tag Archives: rmh

The Royal Melbourne Hospital’s new state-of-the-art Acute Stroke and Neurology Ward opens its doors

Kelton Young sits in a wheel chair and cuts the ribbon to the new ward.
Kelton Young, cutting the ribbon, was the first patient to move to the new Acute Stroke and Neurology Ward on Level 8B.

Funded by The Royal Melbourne Hospital Foundation, with proceeds from The Royal Melbourne Hospital Home Lottery, the new ward features a mix of single and double rooms, natural light, lifting tracks above beds and a dedicated rehabilitation gym.

The new ward has capacity for 31 beds including eight high acuity beds for patients who require increased monitoring.

The Royal Melbourne Hospital’s Director Neurology, Professor Mark Parsons, said the new ward is cutting edge, designed to cater for the increasing number of strokes cared for at the hospital.

“The RMH is the leading stroke centre nationally, and we would be in the top 10 worldwide for providing world-class stroke care,” Professor Parsons said.

“Each year the RMH team treats around 1000 strokes and the numbers are increasing annually.

“The new purpose built stroke ward is the last piece in the comprehensive stroke service we provide to our community. The RMH is already leading in stroke care and research, we are a statewide provider for endovascular clot retrieval and we have Australia’s first Mobile Stoke Unit.

“When time is brain, we are always striving to provide the best, fastest stroke care available. The RMH is one of the few stroke centres in the world to do this within 20 minutes of patients arriving in the emergency department.”

The Acute Stroke and Neurology’s Nurse Unit Manager, Corey Swift, said the new ward now provided patients with something they haven’t had in Melbourne before, a dedicated unit specialising in the care of stroke, including rehabilitation.

“We treat the sickest of the sick, as far as a stroke patient goes,” Corey said.

“The unit will help us give the best care to our patients and provide them with the best outcome for rehabilitation and for getting them home.”

Recognising the signs and symptoms of a stroke can save a life. Remember FAST – F is for face drooping, A is for arms (can I lift them) S is for speech (slurring) and T is for time, it’s critical to get help as soon as possible. Stroke is a medical emergency, always call 000.

2019 Melbourne Health Accelerator calls for applications

Photo of surgeons operating with the Melbourne Health Accelerator logo in the top left hand corner
Photo of surgeons operating with the Melbourne Health Accelerator logo in the top left hand corner

Applications for the 2019 Melbourne Health Accelerator (MHx) cohort are now open!

www.melbournehealthaccelerator.com

The MHx will allow 12 start-ups to physically relocate to the Royal Melbourne Hospital. The 2019 MHx cohort will run for 13 weeks between April 8th – July 5th 2019 and will require a time commitment of 2-3 days each week from at least one founder.

The MHx program involves:

· A semi-structured curriculum to support cohorts through the healthcare accelerator
· Networking with the broader Melbourne Health community of clinicians, researchers and executives
· Mentoring from commercialisation experts
· Engagement with successful health-tech entrepreneurs
· Access to a database of clinical information and case studies through our partnership with the Health Roundtable
· Opportunity for exposure and possible funding through pitch events, invitational local and international exchanges and exhibitions.

MHx welcomes applications from early stage start-ups companies operating between Minimum Viable Product and pre-Series A (in exceptional circumstances start-ups at idea stage could be considered).

Stentrode™ developed for brain treatments without major surgery

Man smiling at the camera, hands in pockets, in Times Sqaure, New York
Tom Oxley, a researcher on the Stentrode, standing in Times Square smiling at the camera

Australian researchers have developed a tiny device that electrically stimulates the brain and could one day be used to treat conditions such as epilepsy and Parkinson’s disease without invasive surgery.

They have shown for the first time that electrical stimulation can be delivered into the brain from a 4 mm diameter Stentrode™ permanently implanted inside a blood vessel.

This technology opens the door for a range of potential treatments that have traditionally required open brain surgery, including deep brain stimulation for Parkinson’s disease and epilepsy.

Deep brain stimulation requires open brain surgery with an electrode implanted via burr hole surgery, where one or more holes are drilled in the skull so the electrodes can penetrate the brain. The Stentrode™ can place electrodes in the brain via blood vessels through a vein in the neck.

The work builds on previous research that showed the Stentrode™ could be used to record brain signals, with the potential to control an exoskeleton in patients with paralysis. This study now shows the Stentrode™ can also deliver targeted stimulation.

PROOF OF CONCEPT

The proof-of-concept study is published in Nature Biomedical Engineering and involved researchers from The University of Melbourne, Florey Institute of Neuroscience and Mental Health, The Royal Melbourne Hospital, Monash University and the company Synchron Australia.

The researchers implanted a 4 mm diameter Stentrode™ into blood vessels in sheep and achieved localised stimulation of brain tissue, all without open-brain surgery. They implanted devices into blood vessels that were adjacent to motor areas of the brain.

“Stimulation-induced responses of the facial muscles and limbs were observed, and were comparable to those obtained with electrodes implanted following invasive surgery,” the researchers wrote.

“A minimally invasive endovascular surgical approach utilising a stent-electrode array is an encouraging safe and efficacious way to stimulate focal regions of brain.”

UNTIL NOW

Until now, it has never been proven that stimulating the brain from inside a blood vessel can achieve focal brain stimulation using a permanently implanted device. Future studies must now determine the safety of stimulation across a range of intensities.

“While additional data is required to validate chronic safety and efficacy of the Stentrode™, our previous research, and literature on the success of commercially available cranial stents and vascular lead wires supports our hypothesis that a Stentrode™ may be a suitable alternative to invasive neural implants,” the researchers said.

Lead researcher Dr Nick Opie said the work built on previous research that showed the Stentrode™ could listen to the motor cortex of the brain.

“By adding the ability to speak to the brain using electrical stimulation, we have created a two-way digital communication device,” Dr Opie said. “In one application, the Stentrode™ could be used as a tool to record the onset of an epileptic seizure, and provide stimulation to prevent it.”

Co-author Dr Sam John said it was the first time such an implant was able to stimulate the brain without needing to perform open brain surgery. He said this work opened the way to making treatment for drug resistant neurological conditions accessible to a greater number of people.

OFFERS HOPE

“This offers hope of less invasive treatments for the symptoms of conditions such as Parkinson’s disease, epilepsy, depression and obsessive compulsive disorder,” he said.

Earlier research, released in 2016, demonstrated that Stentrodes™ implanted into blood vessels next to the motor cortex could pick up brain signals related to movement. The researchers plan to use the Stentrode™ to close the loop, making two-way communication with the brain possible.

In their upcoming clinical trial, the recording Stentrode™ will receive and interpret neural signals and enable a person with Motor Neurone Disease to control communication software.

Eventually it is hoped this technology will be used to help all people suffering from paralysis to control computers, wheelchairs and exoskeletons.

“From within a blood vessel in the head, the Stentrode™ can pick up brain signals when people think about moving”, Dr Opie said. “These can be converted into commands that enable direct-brain control of computers, vehicles or prosthetic limbs. With stimulation, sensory feedback is possible, and people may be able to feel what they are touching.”

 

This article is sourced from our Proud Precinct Partner, the Royal Melbourne Hospital

New treatment combination brings breast cancer hope

Patient Julie with Medical Oncologist and Study Researcher, Dr Sheau Wen Lok.

Combining two cancer drugs has seen a potential breakthrough for women with metastatic breast cancer.

In a world first, breast cancer researchers at The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, successfully combined a drug that has shown promise in the treatment of chronic leukaemia with therapy used to treat breast cancer.

The Royal Melbourne Hospital’s and Peter MacCallum Cancer Centre’s medical oncologist, Professor Geoff Lindeman, principal investigator of the study, said the combination of the two drugs has given researchers and patients a boost in tackling metastatic breast cancer. Professor Lindeman is also a researcher at the Walter and Eliza Hall Institute.

“The primary aim of the study was to determine the safety and tolerability of Venetoclax in combination with Tamoxifen,” Professor Lindeman said. 

“We tested this combination on the basis of our laboratory findings at the Walter and Eliza Hall Institute. Venetoclax is a drug that switches off BCL-2, a protein that helps keep cancer cells alive. Our findings suggest that adding Venetoclax to conventional hormone therapy might boost responses.

“Although the study was aimed at determining safety and finding the right dose, we found that 75% of the women involved in the study experienced an overall improvement or derived clinical benefit.

“This result has provided a basis for further studies with Venetoclax, where the hope would be to produce deeper and more durable responses for women affected by breast cancer.”

Professor Lindeman added this was the first time Venetoclax has been used on solid tumours. 

“Venetoclax is not currently approved in breast cancer and further studies will be required to determine its effectiveness,” Professor Lindeman said.

Venetoclax was developed based on a landmark discovery made in Melbourne during the late 1980s by Walter and Eliza Hall Institute scientists, that the BCL-2 promoted cancer cell survival.

“There were 42 women enrolled in the study, which was conducted at The Royal Melbourne Hospital, Peter MacCallum Cancer Centre and Olivia Newton-John Cancer Centre over the last three years. 

“The drug was well tolerated, and the majority received the maximum dose with minimal side effects. We have now established a new benchmark dose for future studies.

“We are excited by the findings and what it could mean for patients with incurable hormone receptor positive breast cancer.”

Patient Julie was diagnosed with stage 4 breast cancer just before her 60th birthday. She enrolled in the study and was given the combined dose of Venetoclax and Tamoxifen.

Patient Julie with Medical Oncologist and Study Researcher, Dr Sheau Wen Lok.

Patient Julie with Medical Oncologist and Study Researcher, Dr Sheau Wen Lok.

The 10cm tumour in Julie’s breast shrank rapidly in response to the treatment.

“My tumour is undetectable at the moment – the doctors said they couldn’t find it,” Julie said.

“I’m hopeful this research will help other women in future.”

This article is sourced from our proud precinct partner, The Royal Melbourne Hospital